Key Takeaways Medicaid patients have limited access to GLP-1 drugs to treat obesity Only 13 states currently cover the drugs Medicaid spending on the drugs has nonetheless skyrocketed in recent years TUESDAY, Nov
The combination of strong GLP-1 appetite suppression with meaningful GIP-mediated metabolic improvement creates a synergistic effect that exceeds what either receptor could produce alone, a principle similar to why peptide stacking sometimes outperforms individual compounds
As more drugs of this class are approved, hopefully by additional manufacturers, we are likely to see some decrease in unit price
The broader risk with any peptide therapy is using unregulated, online-sourced peptides without medical supervision
HMG-CoA: 3-hydroxy-3-methyl-glutaryl-coenzyme A
M., Rask-Andersen, M., Schioth, H